Analysis of the Influencing Factors of Immunological Nonresponders in Wuhan, China
Table 2
The comparison of follow-up and baseline conditions of the study patients.
Variable
Baseline
Follow-up
Years since HIV diagnosis
0.1 (0.1, 0.2)
3.3 (2.0, 5.7)
0.000
Years since HAART
—
3.0 (1.8, 5.0)
—
Follow-up times
—
15.0 (11.0, 22.0)
—
HAART options
0.000
3TC + TDF + EFV
153 (69.5%)
118 (53.6%)
3TC + AZT + EFV
30 (13.6%)
27 (12.3%)
NVP+3TC + AZT
24 (10.9%)
9 (4.1%)
Others
13 (5.9%)
66 (30.0%)
Co-trimoxazole
0.000
Yes
156 (70.9%)
195 (88.6%)
No
64 (29.1%)
23 (10.5%)
Missing
0 (0.0%)
2 (0.9%)
Liver function impairment
0.000
Yes
98 (44.1%)
74 (33.3%)
No
124 (55.9%)
125 (56.3%)
Missing
0 (0.0%)
23 (10.4%)
Leukopenia
0.000
Yes
91 (41.4%)
46 (20.9%)
No
129 (58.6%)
150 (68.2%)
Missing
0 (0.0%)
24 (10.9%)
Anemia
0.000
Yes
78 (35.5%)
24 (10.9%)
No
144 (64.5%)
174 (78.2%)
Missing
0 (0.0%)
24 (10.9%)
Viral load (copies/ml)
97830.0 (35476.0, 254172.0)
0.0 (0.0, 20.0)
0.000
CD4 counts (cells/μl)
39.0 (20.3, 105.8)
162.0 (128.3, 183.0)
0.000
WBC count (×109/L)
4.2 (3.3, 5.1)
4.8 (4.0, 5.7)
0.000
Plt count (×109/L)
174.0 (135.8, 218.3)
205.5 (170.3, 241.5)
0.000
Hb count (g/L)
128.0 (113.0, 140.0)
144.0 (130.0, 153.0)
0.000
Cr (μmol/L)
71.8 (61.0, 82.5)
70.0 (60.9, 82.0)
0.393
TG (mmol/L)
1.4 (0.9, 1.9)
1.5 (1.0, 2.4)
0.027
TC (mmol/L)
3.8 (3.3, 4.3)
4.4(3.8, 5.0)
0.000
FPG (mmol/L)
5.5(4.9, 6.4)
5.5 (5.2, 6.3)
0.159
AST (U/L)
28.0 (21.0, 37.0)
25.0 (20.0, 31.0)
0.000
ALT (U/L)
23.5 (14.0, 41.0)
20.0 (14.0, 28.5)
0.002
T.BIL (μmol/L)
10.0 (7.5, 12.9)
7.5 (5.6, 10.7)
0.000
HAART, Highly active antiretroviral therapy; 3TC, Lamivudine; TDF, Tenofovir disoproxil; EFV, Efavirenz; AZT, Zidovudine; NVP, Nevirapine; WBC, White blood cell; Plt, Platelet; Hb, Hemoglobin; Cr, Creatinine; TG, Triglyceride; TC, Total cholesterol; FPG, Fasting plasma glucose; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; T.BIL, Total bilirubin. Data are presented as N (%) or Median (IQR). values were determined by χ2 test or Wilcoxon signed rank test.